Usman Baber, MD
Interventional Cardiology · Oklahoma City, OKNPI 1538378427
Payments from drug & device makers
Across 297 payments — averaging $2477.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$644K
- Amgen$42K
- Abbott$28K
- AstraZeneca$15K
- Abiomed$2K
- Edwards Lifesciences$588
- plus $4K from 28 others
What the payments were for
- Consulting fees$45,41359%
- Speaking & faculty fees$11,00014%
- Travel & lodging$8,40611%
- Food & beverage$11,55015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 53 | $644,130 |
| Amgen | 44 | $41,796 |
| Abbott | 29 | $28,136 |
| AstraZeneca | 19 | $15,155 |
| Abiomed | 31 | $2,424 |
| Edwards Lifesciences | 10 | $588 |
| Inari Medical, Inc. | 12 | $473 |
| Medtronic(2 entities) | 9 | $441 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $334 |
| Chiesi USA, Inc. | 14 | $286 |
| Shockwave Medical, Inc | 1 | $193 |
| Merck | 2 | $165 |
| Stryker | 6 | $162 |
| Pulmonx Corporation | 5 | $157 |
| E.r. Squibb & Sons, L.L.C. | 8 | $143 |
| Philips North America LLC | 1 | $142 |
| Penumbra, Inc. | 1 | $138 |
| Novartis | 7 | $125 |
| Johnson & Johnson | 6 | $123 |
| Teleflex LLC | 1 | $120 |
| Baxter Healthcare | 3 | $97 |
| Irhythm Technologies, Inc. | 4 | $68 |
| Janssen Scientific Affairs, LLC | 2 | $66 |
| Cardiovascular Systems Inc. | 1 | $64 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| Pfizer | 3 | $52 |
| Terumo Medical Corporation | 1 | $28 |
| Cardiva Medical, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Insmed, Inc. | 1 | $18 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Asahi Intecc USA, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$32,389
- BRILINTA$14,629
- GENERAL VASCULAR ACCESS$10,140
- Impella$1,983
- DRAGONFLY OPSTAR$1,620
- XIENCE SIERRA$1,129
- MitraClip$757
- FLOWTRIEVER CATHETER, S$396
- WATCHMAN FLX$383
- WATCHMAN Access System$240
- General - Balloon Catheters$238
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$193
- CoreValve Evolut$180
- Edwards SAPIEN 3 Transcatheter Heart Valve$177
- EVOQUE$159
- Turbo Elite$142
- Indigo System$138
- Xience Sierra Coronary Stent System$134
- SYNERGY$131
- COREVALVE EVOLUT R$125
How this compares
$735,796 in reported general payments places this provider in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $91,525 |
| XareltoRivaroxaban | 33 | $32,085 |
| EntrestoSacubitril/Valsartan | 16 | $20,467 |
| FarxigaDapagliflozin Propanediol | 15 | $13,895 |
| Atorvastatin Calcium | 90 | $1,134 |
| Metoprolol Succinate | 83 | $1,079 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 42 | $624 |
| ClopidogrelClopidogrel Bisulfate | 32 | $608 |
| Celecoxib | 14 | $603 |
| Carvedilol | 33 | $582 |
| Bisoprolol Fumarate | 20 | $533 |
| Lisinopril | 48 | $532 |
| Ezetimibe | 28 | $518 |
| Pravastatin Sodium | 30 | $436 |
| Amlodipine Besylate | 44 | $419 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $52 | $91,52567 claims |
| Johnson & JohnsonXarelto | $123 | $32,08533 claims |
| NovartisEntresto | $125 | $20,46716 claims |
| AstraZenecaFarxiga | $15,155 | $13,89515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- Naeem TahirkheliOklahoma City$8.6M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Jeffrey SparlingOklahoma City$381K
- Thomas McGarryOklahoma City$153K
- Faisal LatifOklahoma City$129K
- Branislav SchifferdeckerOklahoma City$121K
- Mazen Abu-FadelOklahoma City$98K
- Dwayne SchmidtOklahoma City$79K
- Marcus SmithOklahoma City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.